When Gleevec Is Not Enough: Researcher Demonstrates Value Of 'Helper' Compound In Treating Some ...

... Researchers at the Jackson Laboratory, in collaboration with scientists at Bristol-Myers Squibb Oncology, discovered is that imatinib does not inactivate all BCR-ABL signaling pathways in the cascade. Proteins called SRC kinases are still activated by BCR-ABL in imatinib-treated mouse leukemic cells. Treatment with dasatinib, which inhibits the SRC proteins as well as BCR-ABL, was not only more effective for CML, but also led to complete B-ALL remission. ...